A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2)
Latest Information Update: 15 May 2025
At a glance
- Drugs AZD 3427 (Primary)
- Indications Heart failure; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms Re-PHIRE
- Sponsors AstraZeneca
Most Recent Events
- 28 Jan 2025 Planned primary completion date changed from 23 Apr 2025 to 15 Jul 2025.
- 28 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 23 Sep 2024 Planned End Date changed from 2 Jun 2025 to 26Aug 2025.